UCB Biopharma SRL Drug Pipeline

UCB Biopharma SRL maintains a substantial clinical development portfolio, with 120 trials registered since 2008 and 33 currently active. The pipeline spans from Phase 1 through Phase 4, with a notable concentration in Phase 3 (25 active trials). Clinical activity is distributed across six therapeutic areas, though heavily weighted toward Immunology, which accounts for 42% of active programs (14 trials). Within Immunology, the leading indications are Psoriatic Arthritis (6 active trials, 4 in Phase 3) and Psoriasis (4 active trials, 3 in Phase 3). Lupus, Ankylosing Spondylitis, and Atopic Dermatitis also have ongoing trials within the Immunology portfolio. Central Nervous System (CNS) indications account for 3 active trials. The remaining therapeutic areas, including Rare Disease, Oncology, Musculoskeletal, and Respiratory, currently have no active trials registered. The portfolio's late-stage concentration in Immunology suggests a focus on near-term clinical catalysts within this therapeutic area.